TY - JOUR AU - Zhu, Xiuzhi AU - Chen, Li AU - Huang, Binhao AU - Li, Xiaoguang AU - Yang, Liu AU - Hu, Xin AU - Jiang, Yizhou AU - Shao, Zhimin AU - Wang, Zhonghua PY - 2021 DA - 2021/04/08 TI - Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer JO - Journal of Experimental & Clinical Cancer Research SP - 122 VL - 40 IS - 1 AB - PARP inhibitors (PARPi) benefit only a fraction of breast cancer patients with BRCA mutations, and their efficacy is even more limited in triple-negative breast cancer (TNBC) due to clinical primary and acquired resistance. Here, we found that the efficacy of the PARPi olaparib in TNBC can be improved by combination with the CDK4/6 inhibitor (CDK4/6i) palbociclib. SN - 1756-9966 UR - https://doi.org/10.1186/s13046-021-01930-w DO - 10.1186/s13046-021-01930-w ID - Zhu2021 ER -